ECU
PTCT icon

Eisler Capital (US)’s PTC Therapeutics PTCT Stock Holding History

Eisler Capital (US)’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-23,779
Closed -$727K – 628
2024
Q2 		$727K Sell
23,779
-546
-2% -$17.7K 0.01% 534
2024
Q1 		$708K Buy
+24,325
New +$681K 0.02% 448

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eisler Capital (US)'s PTCT Position: Q3 2024 in Review

Eisler Capital (US) sold out of PTC Therapeutics (PTCT) in Q3 2024, closing a stake of 23,779 shares — an estimated $727K sold.

Eisler Capital (US) first reported a position in PTCT in Q1 2024 and held it in 2 quarters. The position peaked at $727K in Q2 2024. 203 funds tracked by Wall St. Rank hold PTCT as of Q3 2024.

  • Eisler Capital (US) reported no remaining PTC Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Eisler Capital (US) sold 23,779 PTC Therapeutics shares in Q3 2024, an estimated $727K.
  • Eisler Capital (US) first reported a position in PTC Therapeutics in Q1 2024 and held it in 2 quarters.
  • Eisler Capital (US)'s PTC Therapeutics position peaked at $727K in Q2 2024.
  • 203 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.